vs
Side-by-side financial comparison of Sila Realty Trust, Inc. (SILA) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $50.1M, roughly 1.4× Sila Realty Trust, Inc.). Sila Realty Trust, Inc. runs the higher net margin — 10.0% vs -49.0%, a 59.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 7.6%).
Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SILA vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.1M | $70.6M |
| Net Profit | $5.0M | $-34.6M |
| Gross Margin | 88.9% | — |
| Operating Margin | — | -56.7% |
| Net Margin | 10.0% | -49.0% |
| Revenue YoY | 7.6% | 81958.1% |
| Net Profit YoY | -54.9% | 54.9% |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.1M | — | ||
| Q3 25 | $49.8M | $70.6M | ||
| Q2 25 | $48.7M | — | ||
| Q1 25 | $48.3M | — | ||
| Q4 24 | $46.5M | — | ||
| Q3 24 | $46.1M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $50.6M | — |
| Q4 25 | $5.0M | — | ||
| Q3 25 | $11.6M | $-34.6M | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $7.9M | — | ||
| Q4 24 | $11.1M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $4.6M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | 88.9% | — | ||
| Q3 25 | 88.1% | — | ||
| Q2 25 | 87.7% | — | ||
| Q1 25 | 86.9% | — | ||
| Q4 24 | 87.3% | — | ||
| Q3 24 | 87.4% | — | ||
| Q2 24 | 86.6% | — | ||
| Q1 24 | 89.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 23.3% | -49.0% | ||
| Q2 25 | 17.6% | — | ||
| Q1 25 | 16.4% | — | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | 25.9% | — | ||
| Q2 24 | 10.6% | — | ||
| Q1 24 | 29.6% | — |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.15 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $0.20 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $503.0M |
| Total Assets | $2.1B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.3M | — | ||
| Q3 25 | $27.7M | $490.9M | ||
| Q2 25 | $24.8M | — | ||
| Q1 25 | $30.5M | — | ||
| Q4 24 | $39.8M | — | ||
| Q3 24 | $28.6M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $90.2M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $503.0M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $577.1M | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $119.1M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 23.76× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.1M | — | ||
| Q3 25 | $30.0M | $-84.6M | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $132.8M | — | ||
| Q3 24 | $29.1M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $36.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 23.76× | — | ||
| Q3 25 | 2.59× | — | ||
| Q2 25 | 3.71× | — | ||
| Q1 25 | 3.06× | — | ||
| Q4 24 | 11.95× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 6.84× | — | ||
| Q1 24 | 2.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
